Timeline 6 due · 18 done
Dates for future items are the registry's or the sponsor's guidance; where only a window is known the entry says so and carries a placeholder date inside it. Corrected the day a result is public.
Due
- 2027
PREVAIL outcomes result (obicetrapib)
Interim analysis Q4 2026, results expected Q1 2027
More than 9,500 ASCVD patients; will show whether the CETP inhibitor's LDL-C, apoB and Lp(a) lowering translate into fewer events. Covered in depth on cetpinhibition.org. NewAmsterdam Pharma
CETP inhibitionreadoutEAS Congress 2027
Upcoming
The lipid society's annual congress; the venue where the EAS Lp(a) consensus is likely to be revisited once outcomes data exist. European Atherosclerosis Society
congress- 2029
ACCLAIM-Lp(a) primary completion (lepodisiran)
Enrolment complete; primary completion March 2029
17,300 participants, secondary and primary prevention, dosing about every six months. Eli Lilly
lepodisiranphase 3readout- 2031
MOVE-Lp(a) primary completion (muvalaplin)
Recruiting since September 2025
10,450 participants; the first outcomes trial of an oral Lp(a)-lowering drug. Eli Lilly
oral inhibitionphase 3readoutOCEAN(a)-PreEvent primary completion (olpasiran, primary prevention)
Recruiting since August 2025
11,000 people at risk of a first major cardiovascular event: the first dedicated primary-prevention outcomes trial for Lp(a). Amgen
olpasiranphase 3primary preventionreadout
Done
- 2026
AHA Scientific Sessions 2026
Held
7 to 10 November 2026, Chicago. Lp(a)HORIZON read out neutral in the opening late-breaking session (7 November, NEJM): pelacarsen lowered Lp(a) by 78 percent without reducing events. Lp(a)FRONTIERS EXPANSION (pelacarsen, 86 percent lowering in US Black/African American and Hispanic participants) followed in featured science. American Heart Association
aha 2026congressLp(a)HORIZON result (pelacarsen): neutral
Reported: presented at AHA 2026 (LBS.01) and published in NEJM on 7 November 2026; hazard ratio 1.02 for the primary endpoint
The first cardiovascular outcomes trial of an Lp(a)-lowering therapy. In 8,322 patients with established cardiovascular disease and Lp(a) of 70 mg/dL or more, monthly pelacarsen 80 mg lowered Lp(a) by about 78 percent but the primary endpoint occurred in 12.3 versus 12.1 percent over a median 4.7 years (hazard ratio 1.02, 95 percent CI 0.90 to 1.15), with no effect above 90 mg/dL. Novartis had announced a topline miss in September 2026; the full data came at AHA 2026. Novartis / Ionis
pelacarsenphase 3readoutEuropean Commission decision on obicetrapib (Ubeslo, Evlarco)
Approved: European Commission marketing authorisation granted in September 2026 for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg with ezetimibe 10 mg), the first approval of obicetrapib anywhere
The first approval of a CETP inhibitor, an LDL-C-lowering drug that also lowers Lp(a) by about 37 percent. Indicated for primary hypercholesterolaemia (heterozygous familial and non-familial) and mixed dyslipidaemia, on the BROADWAY, BROOKLYN and TANDEM trials; the PREVAIL outcomes trial continues. Launch by Menarini in Europe follows. NewAmsterdam Pharma / Menarini
CETP inhibitionregulatoryESC Congress 2026, München
Held
28 to 31 August 2026. Twelve Hot Line sessions; Lp(a)HORIZON was not presented here and read out at AHA 2026 instead. The first congress after the CHMP opinion on obicetrapib. European Society of Cardiology
congressESC 2026CHMP positive opinion for obicetrapib (Ubeslo) and obicetrapib/ezetimibe (Evlarco)
The first CETP inhibitor recommended for approval anywhere; also lowers Lp(a) by about 37 percent (Nicholls, EHJ 2026). European Medicines Agency
CETP inhibitionregulatoryLp(a)FRONTIERS APHERESIS published: pelacarsen replaces apheresis
The first phase 3 result for an Lp(a)-specific drug: apheresis sessions cut to 0.16 of the weekly schedule, Lp(a) down 72 percent at 52 weeks. European Heart Journal
apheresispelacarsenphase 32026 ACC/AHA multisociety dyslipidemia guideline published
Replaces the 2018 blood cholesterol guideline; scope now includes lipoprotein(a). Circulation / JACC
guidelines- 2025
2025 ESC/EAS focused update presented at ESC Congress, Madrid
Lp(a) kept as a once-in-a-lifetime measurement and risk modifier. European Society of Cardiology
ESC 2025guidelinesALPACA (lepodisiran phase 2) presented at ACC.25 and published in NEJM
Time-averaged Lp(a) down 93.9 percent from day 60 to 180 after 400 mg. Eli Lilly / NEJM
lepodisiranphase 2- 2024
KRAKEN and ALPACAR presented at AHA 2024
Oral muvalaplin (up to 86 percent) and zerlasiran (more than 80 percent time-averaged) both meet their phase 2 endpoints. AHA Scientific Sessions / JAMA
oral inhibitionphase 2zerlasiran- 2022
OCEAN(a)-DOSE presented at AHA 2022 and published in NEJM
Olpasiran lowers Lp(a) by more than 95 percent at 75 mg or more every 12 weeks. Amgen / NEJM
olpasiranphase 2EAS Lp(a) consensus statement published
Kronenberg, Mora, Stroes and colleagues: the reference document of the current era. European Heart Journal
consensusLp(a)HORIZON completes enrolment (8,323 patients)
Event-driven follow-up begins. Novartis / Ionis
pelacarsenphase 3- 2020
Pelacarsen phase 2 published in NEJM: up to 80 percent Lp(a) lowering
Tsimikas et al.; the dose selection for Lp(a)HORIZON. NEJM
pelacarsenphase 2- 2019
2019 ESC/EAS guidelines: measure Lp(a) once in every adult's lifetime
The first major guideline with universal once-in-a-lifetime Lp(a) measurement. European Society of Cardiology / EAS
guidelines- 2013
LPA identified as the genome-wide signal for aortic valve calcification (NEJM)
Lp(a) becomes a causal factor for calcific aortic valve disease. NEJM
aortic stenosisgenetics- 2009
Causality established: Clarke (NEJM) and Kamstrup (JAMA) Mendelian randomisation studies
LPA variants raise Lp(a) and coronary risk in proportion; the field's turning point. NEJM / JAMA
geneticshistory- 1963
Kåre Berg describes the Lp system
The discovery of lipoprotein(a). Acta Pathologica et Microbiologica Scandinavica
history